Clinical Trial Update: A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing latanoprost formulations to Xalatan for primary open-angle glaucoma and ocular hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• Latanoprost 100 μg/mL (latanoprost)
• Latanoprost 125 μg/mL (latanoprost)
• Latanoprost 75 μg/mL (latanoprost)
• Xalatan (latanoprost)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Primary Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Status: COMPLETED